On August 24, 2021, Azurity Pharmaceuticals, Inc. and Arbor Pharmaceuticals, Inc. announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from existing investors including JW Asset Management and KKR. Following the completion of the transaction, which is subject to regulatory approvals, Azurity and Arbor will merge, creating a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions. Financial details of the transaction were not disclosed.

A Wilson Sonsini Goodrich & Rosati team that advised Azurity on IP and litigation matters related to this transaction includes:

Samir Elamrani
Wendy Devine
Clark Lin
Ying Chen
Johnson Truong
Rida Atif
Joseph Lesniewski

For more information, please see the press release.